PARP阻害剤市場：薬剤タイプ別、用途別、流通チャネル別、地域別

PARP阻害剤の世界市場は、2025年には78億5,000万米ドルと推定され、2032年には143億6,000万米ドルに達すると予測され、2025～2032年にかけてCAGR9.0％で成長すると予測されています。

図.PARP阻害剤市場シェア（%）、2025年地域別

ポリ（ADP-リボース）ポリメラーゼ（PARP）阻害剤は、主にがん治療に用いられる標的治療の一種です。これらは、損傷を受けたDNAを修復するPARP酵素の働きを阻害することで機能するため、化学療法や放射線療法ががん細胞をより効果的に死滅させるのに役立ちます。世界のPARP阻害剤市場の成長は、がん罹患率の上昇、がん治療におけるPARP阻害剤の承認と採用の増加によってもたらされます。同市場の主要薬剤には、乳がん、卵巣がん、前立腺がんなどの治療で有効性が実証されているオラパリブ、ニラパリブ、ルカパリブなどがあります。新たながん種や併用療法におけるPARP阻害剤の可能性を評価する調査が進行中であることから、同市場は成長する可能性があります。

市場力学

PARP阻害剤の世界市場成長の原動力は、世界のがん罹患率の増加と、がん領域におけるPARP阻害剤の承認・採用の拡大です。WHOによると、2018年のがん罹患者数は1,810万人、死亡者数は960万人に増加しています。より広範な患者層におけるPARP阻害剤の有効性を評価する継続的な臨床検査や、他の抗がん治療との併用が、市場の成長を促進する可能性があります。しかし、PARP阻害剤の高価格、患者選択のための遺伝子事前スクリーニングの必要性、医薬品承認のための厳格な規制経路の賦課は、市場成長の妨げとなる可能性があります。新たな用途を模索する継続的な研究や、新たなパイプライン医薬品は、近い将来の市場成長に新たな機会を提供する可能性があります。

本調査の主要特徴

• 本レポートでは、世界のPARP阻害剤市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案のマトリックスについて説明しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界のPARP阻害剤市場の主要企業をプロファイルしています。
• 本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• PARP阻害剤の世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業のさまざまな利害関係者に対応しています。
• 利害関係者は、世界のPARP阻害剤市場分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• 一貫型機会マップ（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 規制シナリオ
• 買収と提携のシナリオ
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界のPARP阻害剤市場-コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界のPARP阻害剤市場、薬剤タイプ別、2020～2032年（10億米ドル）

• イントロダクション
• ニラパリブ
• オラパリブ
• ルカパリブ
• タラゾパリブ
• ベリパリブ
• その他

第6章 世界のPARP阻害剤市場、用途別、2020～2032年（10億米ドル）

• イントロダクション
• 卵巣がん
• 卵管がん
• 乳がん
• 前立腺がん
• 膵臓がん
• その他

第7章 世界のPARP阻害剤市場、流通チャネル別、2020～2032年（10億米ドル）

• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界のPARP阻害剤市場、地域別、2020～2032年（10億米ドル）

• イントロダクション
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• 企業プロファイル
  • AstraZeneca
  • GlaxoSmithKline
  • Merck Co. &Inc
  • AbbVie Inc
  • Clovis Oncology
  • Medivation
  • Johnson & Johnson Services, Inc
  • Pfizer Inc.
  • Genentech, Inc.
  • Artios Pharma
  • Repare Therapeutics Inc.
  • Sierra Oncology, Inc.
  • KaryopharmTherapeutics Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.

第10章 アナリストの推奨事項

• 隆盛と衰退
• 一貫型機会マップ

第11章 参考文献と調査手法

• 参考文献
• 調査手法

Global PARP Inhibitor Market is estimated to be valued at USD 7.85 Bn in 2025 and is expected to reach USD 14.36 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.0% from 2025 to 2032.

Figure. PARP Inhibitor Market Share (%), By Region 2025

Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted therapies used mainly in cancer treatment. These work by blocking the action of PARP enzymes that repair damaged DNA, thus, helping chemotherapy and radiotherapy kill cancer cells more effectively. Global PARP inhibitor market growth is driven by rising cancer incidence, increasing approval and adoption of PARP inhibitors in oncology. Key drugs in the market include Olaparib, Niraparib and Rucaparib which have demonstrated efficacy in treating cancers like breast, ovarian and prostate. With ongoing research evaluating the potential of PARP inhibitors in newer cancer types and combination therapies, the can witness growth.

Market Dynamics:

Global PARP inhibitor market growth is primarily driven by increasing prevalence of cancer worldwide coupled with growing approval and adoption of PARP inhibitors in oncology. According to WHO, cancer burden has increased to 18.1 million new cases and 9.6 million deaths in 2018. Continuous clinical trials evaluating the efficacy of PARP inhibitors in broader patient segments and combination with other anti-cancer therapies can drive the market growth. However, high cost of PARP inhibitors, requirement of genetic pre-screening for patient selection and imposition of stringent regulatory pathways for drug approval can hamper the market growth. Ongoing research exploring newer applications and emerging pipeline drugs can offer new opportunities for market growth in the near future.

Key Features of the Study:

• This report provides in-depth analysis of the global PARP inhibitor market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global PARP inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AstraZeneca, Clovis Oncology, TESARO, AbbVie, Pfizer, Merck KGaA
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global PARP inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP inhibitor market

Detailed Segmentation-

• By Drug Type
  • Niraparib
  • Olaparib
  • Rucaparib
  • Talazoparib
  • Veliparib
  • Others
• By Application
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Breast Cancer
  • Prostate Cancer
  • Pancreatic Cancer
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AstraZeneca
  • GlaxoSmithKline
  • Merck Co. & Inc
  • AbbVie Inc
  • Clovis Oncology
  • Medivation
  • Johnson & Johnson Services, Inc
  • Pfizer Inc.
  • Repare Therapeutics, Inc.
  • Genentech, Inc.
  • Artios Pharma
  • Sierra Oncology, Inc.
  • KaryopharmTherapeutics Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Application
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global PARP Inhibitor Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global PARP Inhibitor Market, By Drug Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Niraparib
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Olaparib
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Rucaparib
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Talazoparib
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Veliparib
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global PARP Inhibitor Market, By Application, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Ovarian Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Fallopian Tube Cancer
  • Mammography
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Breast Cancer
  • Chest X-ray
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Prostate Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pancreatic Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global PARP Inhibitor Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global PARP Inhibitor Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • AstraZeneca
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GlaxoSmithKline
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck Co. & Inc
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AbbVie Inc
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Clovis Oncology
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Medivation
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Johnson & Johnson Services, Inc
  • Pfizer Inc.
  • Genentech, Inc.
  • Artios Pharma
  • Repare Therapeutics Inc.
  • Sierra Oncology, Inc.
  • KaryopharmTherapeutics Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact